Tempest Therapeutics, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Tempest Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2026-03-31 was $170.00K, a 88.23% decline year-over-year.
- Tempest Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2025-06-30 was $3.57M.
- Tempest Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2025-03-31 was $1.44M.
- Tempest Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2023-09-30 was $20.00K, a 94.29% decline year-over-year.
- Tempest Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2025 was $6.05M, a 78.85% decline from fiscal 2024.
- Tempest Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2024 was $28.59M, a 19.68% decline from fiscal 2023.
- Tempest Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2023 was $35.60M, a 301.74% increase from fiscal 2022.
- Tempest Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2022 was $8.86M, a 73.53% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-03-31 | $170.00K 10-Q · filed 2026-08-13 | |
| 2025-12-31 | $6.05M 10-K · filed 2026-03-30 | |
| 2025-06-30 | $3.57M 10-Q · filed 2026-08-13 | |
| 2025-03-31 | $1.44M 10-Q · filed 2026-05-14 | |
| 2024-12-31 | $28.59M 10-K · filed 2026-03-30 | |
| 2023-12-31 | $35.60M 10-K · filed 2025-03-27 | |
| 2023-09-30 | $20.00K 10-Q · filed 2024-11-12 | $8.71M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $1.19M 10-Q · filed 2024-11-12 | $9.04M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-03-31 | $44.00K 10-Q · filed 2024-11-12 | $14.95M derived: sum of 4 quarters · filed 2024-11-12 |
| 2022-12-31 | $7.46M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $8.86M 10-K · filed 2024-03-19 |
| 2022-09-30 | $350.00K 10-Q · filed 2023-11-08 | $8.80M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $7.09M 10-Q · filed 2023-11-08 | $11.96M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-03-31 | $1.40M 10-Q · filed 2023-11-08 | $34.88M derived: sum of 4 quarters · filed 2023-11-08 |
| 2021-12-31 | -$49.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $33.47M 10-K · filed 2023-03-22 |
| 2021-09-30 | $3.51M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $30.01M 10-Q · filed 2022-11-08 | |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | $5.65M 10-K · filed 2021-03-29 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | |
| 2020-03-31 | $5.65M 10-Q · filed 2021-05-13 | |
| 2019-12-31 | $26.49M 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B |